Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Bradley Kay was left 'broken' after supplying 15 MDMA pills to his friend Cameron Johnson, 22, who collapsed at Forum ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...